Protocol recommendations for administration of intravenous immunoglobulin in Canada

Journal of Infusion Nursing

Volumn 29, Issue 3, 2006, Pages 158-164

  Reid, Brenda ^a,b   Van Allen, Donna ^c   Lagrange, Carole Ann ^d   Boissonneault, Nathalie ^e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Canadian Immunodeficiency Society   (Canada)

^c Grand River Regional Cancer Centre   (Canada)

^d Centre Hospitalier Universitaire de Québec ^*

^e LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

CANADA; CLINICAL PROTOCOL; DRUG CONTRAINDICATION; DRUG INFUSION; DRUG SAFETY; EQUIPMENT; FILTER; HIGH RISK PATIENT; HUMAN; INFORMED CONSENT; INFUSION PUMP; MEDICAL DOCUMENTATION; NURSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DOCUMENTATION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL RECORD; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; PATIENT CARE PLANNING; PATIENT SELECTION; PRACTICE GUIDELINE; RISK ASSESSMENT; SAFETY; STANDARD;

CANADA; CLINICAL PROTOCOLS; DOCUMENTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFORMED CONSENT; INFUSIONS, INTRAVENOUS; NURSE'S ROLE; NURSING ASSESSMENT; NURSING RECORDS; PATIENT CARE PLANNING; PATIENT SELECTION; PRACTICE GUIDELINES; RISK ASSESSMENT; SAFETY MANAGEMENT;

EID: 33747628037     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129804-200605000-00006     Document Type: Review

References (33)

1. British Columbia Provincial Blood Coordinating Office. IVIG Utilization Management Handbook. 1st ed. Vancouver, BC: Ministry of Health Services; 2002.
2. Knapp MJ, Colburn PA. Clinical uses of intravenous immune globulin. Clin Pharm. 1990;9(12):909, 912.
3. National Institute of Health. Intravenous immunoglobulin. Consensus Statement. 1990;8(5):1-23.
4. Timmerman PR. Intravenous immunoglobulin in oncology nursing practice. Oncol Nurs Forum. 1993;20(1):69-75.
5. Bussel JB. The use of intravenous gamma-globulin in idiopathic thrombocytopenic purpura. Clin Immunol Immunopathol. 1989;53(2 Pt 2):S147-S155.
6. Carroll RR, Noyes WD, Rosse WF, et al. Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. Am J Med. 1984;76(3A):181-186.
7. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gammaglobulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17(12):1144-1148.
8. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341-347.
9. Hanna K, Poulin-Costello M, Preston M, et al. Intravenous immune globulin use in Canada. Can J Clin Pharmacol. 2003;10(1):11-16.
10. Nobile-Orazio E, Terenghi F. IVIG in idiopathic autoimmune neuropathies: analysis in the light of the latest results. J Neurol. 2005;252(Suppl 1):7-13.
11. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43:1460-1480.
12. Brannagan TH III. Intravenous gammaglobulin (IVIG) for treatment of CIDP and related immune-mediated neuropathies. Neurology. 2002;59(12 Suppl 6):S33-S40.
13. Besa EC. Use of intravenous immunoglobulin in chronic lymphocytic leukemia. Am J Med. 1984;76(3A):209-218.
14. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902-907.
15. Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333-340.
16. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990;323(11):705-712.
17. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IVIG-C, 10% (caprylate/chromatography) and IVIG-SD, 10% as replacement therapy in primary immune deficiency: a randomized double-blind trial. Int Immunopharmacol. 2003;3(9):1325-1333.
18. Brennan VM, Salomé-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133:247-251.
19. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17(4):241-251.
20. Shah S, Vervan M. Use of IV immune globulin and occurrence of associated renal failure and thrombosis. Am J Health-Syst Pharm. 2005;62:720-725.
21. Product monograph. Gamunex immune globulin intravenous (Human), 10% manufactured by chromatography (10, 25, 50, 100, and 200 mL): passive immunizing agent. Clayton, NC: Bayer, Inc; August 11, 2003.
22. Product monograph. Gamimune N, 10%. Clayton, NC: Bayer; May 12, 1999.
23. Product monograph. Gammagard SD. Deerfield, Ill: Baxter International, Inc. November 2000.
24. Product monograph. Iveegam Immuno. Deerfield, Ill: Baxter International, Inc. July 2000.
25. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J. 1997;16(7):696-707.
26. Shah S. Pharmacy considerations for the use of IVIG therapy. Am J Health-Syst Pharm. 2005;62(Suppl 3):S5-S11.
27. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf. 1993;9(4):254-262.
28. Paran D, Herishanu Y, Elkayam O, et al. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16(5):313-318.
29. US Pharmacopeial Convention, Inc. Pharmaceutical compounding - sterile preparations. In: US Pharmacopeia 2. Chapter 9. Rockville, MD: US Pharmacopeial Convention, Inc.; 2005.
30. Davis J, Duff K, Ganio S, et al. Criteria for selecting an IVIG preparation: the infusion nurses' perspective. J Allergy Clin Immunol. 2003;111(2 Pt 2):a208.
31. Ballow M, Berger M, Bonilla FA, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IVIG-C 10% (Gamunex 10%). Vox Sang. 2003;84:202-210.
32. Bussel JB, Eldor A, Kelton JG, et al. IVIG-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. IVIG-C in ITP Study Group. Thromb Haemost. 2004;91(4):771-778.
33. Murphy E, Martin S, Patterson JV. Developing practice guidelines for the administration of intravenous immunoglobulin. J Infus Nurs. 2005;28(4):265-272.